Is Orlistat the Same as Mounjaro? Two Very Different Medicines

You're reading a comparison article at 11pm because something in the trial figures didn't add up

That is a reasonable place to be. The search results for weight-loss medicines are a jumble of brand names, generic names and repurposed diabetes drugs, and it is genuinely hard to tell what is competing with what. Orlistat and Mounjaro are both used in weight management, so they show up in the same searches. But they belong to completely different drug classes and have almost nothing in common once you get past that broad category.

Orlistat works in the gut. It inhibits pancreatic and gastric lipases, the enzymes that break down dietary fat so your body can absorb it. Block those enzymes and roughly a third of the fat in a meal passes through undigested. The practical implication is that what you eat matters enormously: a high-fat meal on orlistat typically produces very uncomfortable gastrointestinal side effects, which is partly what gives it its reputation as a medicine that enforces dietary discipline. The NHS orlistat medicines page covers this mechanism and its common effects in detail.

Mounjaro works upstream. Tirzepatide, the active ingredient, activates both the GIP and GLP-1 receptors involved in regulating appetite, blood sugar and the rate at which the stomach empties. Hunger is quieter. Meals feel filling sooner. That hormonal shift is why people on Mounjaro often report that their relationship with food feels different, not just that they are eating less by willpower. Our tirzepatide overview goes into the mechanism in more depth if you want the fuller picture.

What the trial evidence actually shows for each

This is where the gap becomes hard to ignore. In the SURMOUNT-1 trial, published in the New England Journal of Medicine, adults taking tirzepatide at the highest dose (15mg) lost an average of around 20–21% of body weight over 72 weeks. That is a clinically significant figure, for a 100kg person, that is 20kg or more on average. The trial involved 2,539 participants, and results were broadly consistent across the cohort. NICE's appraisal of tirzepatide (TA1026) reviewed this evidence in full before recommending the medicine for NHS use.

Orlistat trials have generally shown more modest outcomes. In studies conducted alongside a calorie-reduced diet and lifestyle support, average weight loss in the range of 5–10% is the figure most often cited in the clinical literature. That can be a meaningful result for some people, particularly those for whom a fat-absorption block is the right fit. But it is a different order of magnitude from the hormone-based medicines, and patients switching from one to the other sometimes feel the comparison was not clearly explained to them at the start.

For a more direct side-by-side look, our page on whether orlistat is as effective as Mounjaro covers the evidence in structured detail. The short answer is that they are not directly comparable, different mechanisms, different patient populations in trials, different scale of effect.

Prescription, access and what each medicine asks of you day to day

Orlistat 60mg capsules can be bought without a prescription from a registered pharmacist, though the pharmacist should still assess suitability. The 120mg prescription-strength version requires a clinical assessment and is available on the NHS and privately. Mounjaro is a prescription-only medicine in all strengths, which means a prescriber must assess your medical history, current medications, BMI and any relevant conditions before it can be dispensed. There is no over-the-counter route.

Day to day, orlistat means taking a capsule with each main meal and managing dietary fat carefully to avoid the unpleasant side effects that result from fatty meals. Mounjaro is a once-weekly subcutaneous injection; the pen is small, pre-filled, and most people manage it straightforwardly after the first use. Treatment starts at 2.5mg to allow your system to adjust, and the prescriber titrates the dose from there. For a broader look at how Mounjaro is used in practice, the Mounjaro treatment page covers the schedule, storage and what to expect.

Cost is also a real consideration. Mounjaro's private price has risen significantly since Eli Lilly's list-price increase in September 2025, with typical private prices ranging roughly £149–£375 per month depending on dose and provider. Orlistat is considerably cheaper. If price is the primary driver of the decision, the UK Mounjaro price comparison guide explains what is and is not usually included in the figures you see advertised. Worth reading before drawing conclusions.

Which one might be right for you, and who actually makes that call

The honest answer is that neither this page nor any comparison article can answer that. Eligibility for Mounjaro on a private prescription requires a BMI of 30 or above, or 27 or above alongside at least one weight-related condition such as high blood pressure, high cholesterol, type 2 diabetes or obstructive sleep apnoea. Orlistat has its own eligibility criteria. Both have contraindications worth discussing with a prescriber.

If you are weighing up the two because you have been on orlistat and want to understand whether Mounjaro is a step worth exploring, that is exactly the kind of question a prescriber should hear directly. The page on orlistat and Mounjaro used together addresses a related question some people have about combining the two (spoiler: it requires careful clinical thought). Some patients also ask whether there is any scenario in which both make sense simultaneously, our page on taking orlistat with Mounjaro sets out what is known.

If you would like a prescriber at nume to review your circumstances and talk through your options, a free consultation is the place to start. No commitment, no algorithm reading your answers. A real clinician looks at your case and gives you a plain answer about whether Mounjaro is clinically appropriate for you. Start your free consultation here.